These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24763133)

  • 1. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
    Wyant T; Leach T; Sankoh S; Wang Y; Paolino J; Pasetti MF; Feagan BG; Parikh A
    Gut; 2015 Jan; 64(1):77-83. PubMed ID: 24763133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
    Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
    N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
    Milch C; Wyant T; Xu J; Parikh A; Kent W; Fox I; Berger J
    J Neuroimmunol; 2013 Nov; 264(1-2):123-6. PubMed ID: 24067534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.
    Kaech C; Pache I; Bürgisser P; Elzi L; Darling KE; Cavassini M
    J Infect; 2012 Aug; 65(2):157-64. PubMed ID: 22410383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
    Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
    Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of gut specific leucocyte recruitment in IBD by vedolizumab.
    Eksteen B
    Gut; 2015 Jan; 64(1):8-10. PubMed ID: 24946955
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
    Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
    Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
    Zanetti AR; Mariano A; Romanò L; D'Amelio R; Chironna M; Coppola RC; Cuccia M; Mangione R; Marrone F; Negrone FS; Parlato A; Zamparo E; Zotti C; Stroffolini T; Mele A;
    Lancet; 2005 Oct 15-21; 366(9494):1379-84. PubMed ID: 16226616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Zhu FC; Hou LH; Li JX; Wu SP; Liu P; Zhang GR; Hu YM; Meng FY; Xu JJ; Tang R; Zhang JL; Wang WJ; Duan L; Chu K; Liang Q; Hu JL; Luo L; Zhu T; Wang JZ; Chen W
    Lancet; 2015 Jun; 385(9984):2272-9. PubMed ID: 25817373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.
    Jafarzadeh A; Montazerifar SJ
    J Ayub Med Coll Abbottabad; 2006; 18(4):4-9. PubMed ID: 17591001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on antibody response to revaccination of hepatitis B vaccine among firstly low-response adults].
    Feng Y; Yan BY; Zhang L; Lü JJ; Liu JY; Gong XH; Cui FQ; Liang XF; Chen SY; Xu AQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Sep; 46(9):813-7. PubMed ID: 23157885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.